Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 328

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 328
---
 September 30, 2025, which was primarily driven by purchases of marketable securities of $282.1 million and purchases of property and equipment of $0.2 million, partially offset by maturities of marketable securities of $141.0 million.

23

Net cash used in investing activities was $142.1 million during the nine months ended September 30, 2024, due to purchases of marketable securities of $175.6 million, partially offset by maturities of marketable securities of $33.5 million.

Financing Activities

Net cash provided by financing activities was $204.1 million during the nine months ended September 30, 2025, primarily due to net proceeds of $202.1 million received when the Company closed its IPO plus exercise proceeds totaling $2.0 million.

Net cash provided by financing activities was $180.4 million during the nine months ended September 30, 2024, during which time the Company closed its Series C Financing.

Future Funding Requirements

As of September 30, 2025, we had cash, cash equivalents and marketable securities of $325.0 million. Based upon our current operating plans, we believe that our existing cash, cash equivalents and investments in marketable securities, will be sufficient to fund our operations into 2028. However, our forecast for the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Additionally, conducting preclinical studies and clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. We will need to raise substantial additional capital in the future.

Our future funding requirements will depend largely on:

•the type, number, scope, progress, expansions, results, costs and timing of, discovery, preclinical studies and clinical trials of our current and future product candidates;

•the costs and timing of manufacturing for our current and future product candidates and commercial manufacturing;

•the costs, timing and outcome of regulatory review of our current and future product candidates;

•the timing and amount of milestones, royalties, or other payments we may be required to make to third parties, including Sanofi SA, the Cystic Fibrosis Foundation and AbbVie, and the terms and timing of establishing and maintaining any other similar arrangements we may enter in the future;

•the legal costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;

•our efforts to enhance